Lipid-Lowering Agents - United States

United States

The revenue of the Lipid-Lowering Agents market in the United States is projected to reach €4.14bn by 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of -0.19%, leading to a market volume of €4.10bn by 2029.
When compared globally, United States is expected to generate the highest revenue, with €4.14bn in 2024.
The United States remains at the forefront of research and development in lipid-lowering agents, with a strong emphasis on innovation and new drug discovery.

Key regions: Europe, Brazil, France, Australia, Germany

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Lipid-Lowering Agents in the United States has been increasing steadily over the years.

Customer preferences: The United States has a large aging population, and as people age, the risk of developing high cholesterol and other cardiovascular diseases increases. This has led to a growing demand for Lipid-Lowering Agents in the country. Additionally, there has been an increase in awareness about the benefits of these drugs, which has led to more people seeking treatment for high cholesterol.

Trends in the market: One of the main trends in the Lipid-Lowering Agents market in the United States is the increasing use of combination therapies. This involves using two or more drugs to treat high cholesterol, which has been found to be more effective than using a single drug. Another trend is the growing popularity of generic drugs, which are more affordable than brand-name drugs.

Local special circumstances: The United States has a well-established healthcare system, which has contributed to the growth of the Lipid-Lowering Agents market in the country. Additionally, the country has a large pharmaceutical industry, which has led to the development of new and innovative drugs for treating high cholesterol.

Underlying macroeconomic factors: The United States has a strong economy, which has enabled more people to afford Lipid-Lowering Agents. Additionally, the country has a high prevalence of high cholesterol and other cardiovascular diseases, which has created a large market for these drugs. The government has also played a role in promoting the use of Lipid-Lowering Agents by providing insurance coverage for these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.